Lercanil (Lercanidipine Hydrochloride)

Lercanidipine Hydrochloride selectively inhibits L‑type calcium channels on vascular smooth‑muscle cells. This blockade prevents calcium entry, causing relaxation of arterial smooth muscle, vasodilation, and a reduction in peripheral vascular resistance, which together lower systemic blood pressure.

The appropriate dose of Lercanil is determined by the prescribing healthcare professional based on the individual’s blood pressure response, age, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Lercanil in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Lercanil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details, and any required import documentation.

Lercanil belongs to the calcium channel blocker class, offering once‑daily dosing and a favorable side‑effect profile compared with some beta‑blockers or diuretics. Its high lipophilicity provides a prolonged duration of action, making it an effective option for patients who need consistent blood‑pressure control.

Lercanil should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight to maintain stability throughout its shelf life.

Lercanil is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, though rare, include severe hypotension, angioedema, and hepatic dysfunction. Patients should seek immediate medical attention if they experience sudden dizziness, swelling of the face or throat, or signs of liver injury such as jaundice or dark urine.

Lercanil is contraindicated in patients with known hypersensitivity to Lercanidipine or any component of the formulation. Caution is advised in individuals with severe hepatic impairment, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors without medical supervision.